Brief: Transgene Receives Approval To Start Phase I Trial Of TG6050

Transgene SA

06/01/2023 06:31

Jan 6 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE RECEIVES APPROVAL TO START A PHASE I TRIAL OF
TG6050,
A NOVEL IL-12-ARMED ONCOLYTIC VIRUS GIVEN BY INTRAVENOUS
ADMINISTRATION
    * PHASE I TRIAL, NAMED DELIVIR, WILL EVALUATE INTRAVENOUS
(IV)
ADMINISTRATION OF THIS NOVEL MULTI-ARMED IMMUNOTHERAPY IN
PATIENTS WITH NON-SMALL CELL LUNG CANCER.
    * TG6050 IS EXPECTED TO ELICIT A POWERFUL AND MULTI-PRONGED
ANTITUMOR RESPONSE
    * DELIVIR TRIAL WILL ENROLL UP TO 36 PATIENTS WITH ADVANCED
NSCLC
WHO HAVE FAILED STANDARD THERAPEUTIC OPTIONS
    * FIRST PATIENT IS EXPECTED TO BE ENROLLED IN THIS
MULTICENTER
TRIAL IN FIRST HALF OF 2023

Source text for Eikon:  ID:nBwcfQqVpa 
Further company coverage:  TRNG.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))